News

Tempest Receives Orphan Drug Designation from the European Medicines Agency for Amezalpat for the Treatment of Patients with HCC
EMA Orphan Drug Designation (ODD) builds on U.S. Food & Drug Administration (FDA) ODD and Fast Track Designation, ...
Vietnam Investment Review on MSN7d
Innovent presents updated IBI363 data in colorectal cancer at ASCO 2025
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, ...
Low-cost HIV drug to improve vision in patients with common diabetes complication
An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
Le Lézard4d
CNS Pharmaceuticals' Chief Medical Officer, Sandra Silberman, MD, PhD to Present at the 2025 Brain Tumor Biotech Summit
AM ET to discuss Company's lead program, TPI 287, in development for treatment of glioblastoma multiforme (GBM) HOUSTON, TX / ACCESS Newswire / June 5, 2025 / CNS Pharmaceuticals, ...
Ahmedabad Mirror10d
Low-cost HIV drug may improve vision in those with diabetes issues
An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
Inexpensive HIV drug can improve vision in patients with common diabetes complication, clinical trial suggests
An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
Health Rounds: HIV pill improves diabetic eye disease without injections
An inexpensive pill for treating HIV could become an alternative to injections for diabetic eye disease, a small study ...
News-Medical.Net on MSN13d
Affordable HIV drug shows promise in improving vision for diabetic eye disease
An inexpensive, long-approved HIV drug can improve vision in patients with a blinding complication of diabetes more ...
Mirage News9d
Pfizer Combo Halves Death Risk in BRAF V600E Cancer
Pfizer Inc. (NYSE: PFE) today announced statistically significant and clinically meaningful survival results from the Phase 3 ...
Tempest Therapeutics stock rises on EMA Orphan Drug Designation
Investing.com -- Shares of Tempest Therapeutics Inc (NASDAQ: TPST) climbed 5.3% following the announcement that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its cancer ...